MG
AVTX icon

Michael Gelband’s Avalo Therapeutics AVTX Stock Holding History

Michael Gelband’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305K Sell
16,495
-1,256
-7% -$19.9K ﹤0.01% 1350
2026
Q1 		$265K Sell
17,751
-14,516
-45% -$227K ﹤0.01% 1337
2025
Q4 		$586K Buy
+32,267
New +$545K ﹤0.01% 1151
2022
Q1 		– Sell
-4
Closed -$18K – 2185
2021
Q4 		$18K Buy
+4
New +$24K ﹤0.01% 2085
2019
Q2 		– Sell
-5
Closed -$77K – 1094
2019
Q1 		$77K Buy
+5
New +$74.8K 0.01% 623

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Michael Gelband's AVTX Position: Q2 2026 in Review

Michael Gelband reduced its Avalo Therapeutics (AVTX) stake by 7.1% in Q2 2026, selling an estimated $19.9K and leaving 16,495 shares worth $305K. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

Michael Gelband first reported a position in AVTX in Q1 2019 and has held it in 5 quarters since. The position peaked at $586K in Q4 2025. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Michael Gelband held 16,495 shares of Avalo Therapeutics worth $305K as of Q2 2026.
  • Michael Gelband sold 1,256 Avalo Therapeutics shares in Q2 2026, an estimated $19.9K.
  • Avalo Therapeutics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1350 holding.
  • Michael Gelband first reported a position in Avalo Therapeutics in Q1 2019 and has held it in 5 quarters since.
  • Michael Gelband's Avalo Therapeutics position peaked at $586K in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.